NAP (Davunetide)

NAP's primary mechanism involves interaction with tubulin heterodimers and microtubule-associated protein tau (MAPT). NAP binds to the beta-tubulin protofilament interface, reducing the critical concentration of tubulin required for polymerization and stabilizing microtubule dynamics. This directly counteracts the microtubule destabilization caused by hyperphosphorylated tau, one of the key pathological events in Alzheimer's disease, PSP, CTE, and FTLD-tau. Stable microtubules are essential for axonal transport of organelles, synaptic vesicles, and neurotrophic factors; microtubule collapse causes the "synaptic starvation" that underlies progressive cognitive decline in tauopathies.

Beyond microtubule stabilization, NAP reduces reactive oxygen species accumulation in neurons challenged with oxidative stressors, glutamate excitotoxicity, and beta-amyloid toxicity. The mechanism involves activation of Nrf2-driven antioxidant gene expression and preservation of mitochondrial membrane potential. In a remarkable demonstration of potency, femtomolar (10^-15 M) concentrations of NAP provide significant neuronal protection, orders of magnitude below the doses of most neuroprotective compounds. This extreme potency suggests a catalytic or signaling amplification mechanism rather than simple stoichiometric interaction with a target.

NAP promotes dendritic spine growth and synaptic protein expression in hippocampal neurons. It increases expression of PSD-95, synaptophysin, and GluR1 (AMPA receptor subunit), proteins essential for synaptic plasticity and long-term potentiation. In aged rodents and Alzheimer's model mice, NAP treatment improves spatial memory (Morris water maze) and object recognition. The combination of microtubule stabilization (preserving axonal transport) and synaptic protein upregulation creates a comprehensive cognitive enhancement mechanism.

The DAVUNETIDE trial (Boxer et al, 2014, Lancet Neurology) randomized 313 PSP patients to intranasal davunetide (60 mg twice daily) or placebo for 52 weeks. The primary endpoint (PSP rating scale and Schwab England ADL) was not met. However, CSF tau levels significantly decreased in the davunetide group (p=0.04), and several secondary cognitive and functional endpoints showed positive trends. The negative primary outcome may reflect PSP's aggressive progression rate overwhelming a neuroprotective effect, or may indicate tau reduction alone is insufficient for clinical benefit in established PSP.

Davunetide showed significant improvement in cognitive outcomes in a Phase II schizophrenia trial, particularly on working memory and attention measures. The connection to schizophrenia came from the finding that ADNP is one of the most consistently downregulated genes in postmortem schizophrenia brain tissue. Two intranasal davunetide trials (Javitt et al) showed improvements on MCCB (MATRICS Consensus Cognitive Battery) and P300 cognitive ERP measures. These remain among the most promising Phase II cognitive results in schizophrenia pharmacology.

De novo mutations in the ADNP gene cause ADNP syndrome, an autism spectrum/intellectual disability condition affecting approximately 1 in 2,000 individuals. The direct causal link between ADNP dysfunction and autism has made NAP the subject of intense investigation as a potential treatment. Mouse models of ADNP syndrome show profound cognitive and social behavior deficits rescued by NAP treatment. Phase II trials in ADNP syndrome children are underway (Alcobra/Coronis clinical program).